drugset / Trial / NCT03815825

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

NCT03815825 ↗

Phase 2 Completed 332 enrolled Ionis Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).

Timeline

Start
2019-03-04
Primary completion
2024-04-18
Completion
2024-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IONIS-FB-LRx Antisense oligonucleotide — Subcutaneous